Sue Brown
6
2
2
2
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 55/100
16.7%
1 terminated/withdrawn out of 6 trials
66.7%
-19.9% vs industry average
0%
0 trials in Phase 3/4
150%
3 of 2 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (6)
Adaptive Biobehavioral Control (ABC) in a Closed-Loop System
Role: lead
Insulin Delivery With Self-Adjusting Closed-Loop and Behavioral Glycemic Control Enhanced by Prediction
Role: lead
Early Feasibility Study of Adaptive Advisory/Automated (AAA) Control of Type 1 Diabetes
Role: lead
Safety and Feasibility of a Machine-Learning Bolus Priming Added to Existing Control Algorithm
Role: lead
Effectiveness of Artificial-Intelligence (AI) Bolus Priming Added to an Existing Fully Automated Control Algorithm (AIDANET)
Role: lead
A Randomized Parallel Clinical Trial of AIDANET, an Automated Insulin Delivery Algorithm, in Fully Closed-Loop Vs Hybrid Closed-Loop Mode In Adults With Type 1 Diabetes (AIDANET At Home)
Role: lead
All 6 trials loaded